

# Giacomo Sgalla

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8679864/giacomo-sgalla-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32  
papers

540  
citations

12  
h-index

23  
g-index

41  
ext. papers

794  
ext. citations

5.7  
avg, IF

4.12  
L-index

#	Paper	IF	Citations
32	COVID-related fibrosis: insights into potential drug targets. <i>Expert Opinion on Investigational Drugs</i> , <b>2021</b> , 1-13	5.9	3
31	An updated safety review of the drug treatments for idiopathic pulmonary fibrosis. <i>Expert Opinion on Drug Safety</i> , <b>2021</b> , 20, 1035-1048	4.1	2
30	Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials. <i>Expert Opinion on Emerging Drugs</i> , <b>2021</b> , 26, 93-101	3.7	2
29	Residual respiratory impairment after COVID-19 pneumonia. <i>BMC Pulmonary Medicine</i> , <b>2021</b> , 21, 241	3.5	5
28	Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility Study. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 1743-1746	4.7	
27	Phase three clinical trials in idiopathic pulmonary fibrosis. <i>Expert Opinion on Orphan Drugs</i> , <b>2021</b> , 9, 1-11	1.1	0
26	Advances with pharmacotherapy for the treatment of interstitial lung disease.. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 1-13	4	
25	Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. <i>Respirology</i> , <b>2020</b> , 25, 1144-1151	3.6	3
24	Progressive Fibrosing Interstitial Lung Disease. A Proposed Integrated Algorithm for Management. <i>Annals of the American Thoracic Society</i> , <b>2020</b> , 17, 1199-1203	4.7	3
23	Antibody-based therapies for idiopathic pulmonary fibrosis. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 779-786	5.4	6
22	Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 771-777	5.9	15
21	Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends. <i>BMC Pulmonary Medicine</i> , <b>2020</b> , 20, 249	3.5	2
20	X-ray Micro-Computed Tomography for Nondestructive Three-Dimensional (3D) X-ray Histology. <i>American Journal of Pathology</i> , <b>2019</b> , 189, 1608-1620	5.8	24
19	Digital Lung Auscultation: Will Early Diagnosis of Fibrotic Interstitial Lung Disease Become a Reality?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 261-263	10.2	3
18	Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	0
17	Update in Pulmonary Fibrosis 2018. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 292-300	10.2	6
16	Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis. <i>Expert Review of Respiratory Medicine</i> , <b>2019</b> , 13, 39-51	3.8	16

15	Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	6
14	Nintedanib for the treatment of idiopathic pulmonary fibrosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 167-175	4	36
13	Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 9-10 <sup>10.2</sup>		4
12	"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease. <i>BMC Pulmonary Medicine</i> , <b>2018</b> , 18, 103	3.5	22
11	Idiopathic pulmonary fibrosis: pathogenesis and management. <i>Respiratory Research</i> , <b>2018</b> , 19, 32	7.3	174
10	Management of Idiopathic Pulmonary Fibrosis <b>2018</b> , 55-63		1
9	The safety of new drug treatments for idiopathic pulmonary fibrosis. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 1483-1489	4.1	15
8	Novel drug targets for idiopathic pulmonary fibrosis. <i>Expert Review of Respiratory Medicine</i> , <b>2016</b> , 10, 393-405	3.8	16
7	Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. <i>JCI Insight</i> , <b>2016</b> , 1,	9.9	47
6	Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report. <i>Journal of Medical Case Reports</i> , <b>2016</b> , 10, 127	1.2	2
5	Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history. <i>Respirology</i> , <b>2016</b> , 21, 427-373.6		90
4	Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. <i>BMC Medicine</i> , <b>2015</b> , 13, 277	11.4	21
3	Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy. <i>BMJ Open Respiratory Research</i> , <b>2015</b> , 2, e000065	5.6	13
2	Therapeutic approach and molecular targets for novel treatments <b>2015</b> , 176-195		
1	Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going. <i>Current Respiratory Care Reports</i> , <b>2012</b> , 1, 216-223		